Remowell2

REMOWELL2 is designed to reduce the intensity and duration of post-operative severe delirium in patients undergoing cardiac surgery, thanks to its unique and patented cardiotomy features that can reduce lipids and leukocytes coming from pericardial suction blood.

Evidence in the literature2 shows that the REMOWELL technology offers efficient LME filtration (Lipid Micro Emboli) in the clinical setting and the subsequent attenuation of NSE release, a known marker of neurological injury. In addition, significantly lower concentration of cystatin C, a known biomarker of kidney function, was found in the postoperative period, suggesting a renoprotective role for LME filtration.

The Remowell filtration technology effectively contributes to reduce the intensity and duration of post-operative delirium with a reduced need for active involvement of intensive care personnel with the patient.